Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [41] A Phase II Stud of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
    Chen, Christine
    Paul, Harminder
    Xu, Wei
    Kukreti, Vishal
    Trudel, Suzanne
    Wei, Ellen
    Li, Zhi Hua
    Brandwein, Joseph
    Pantoja, Mariela
    Leung-Hagensteijn, Chungyee
    BLOOD, 2008, 112 (11) : 23 - 23
  • [42] Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia (CLL).
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 360B - 361B
  • [43] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'Brien, Susan
    Yenerel, Mustafa Nuri
    Illes, Arpad
    Kay, Neil
    Garcia-Marco, Jose A.
    Mato, Anthony
    Pinilla-Ibarz, Javier
    Seymour, John F.
    Lepretre, Stephane
    Stilgenbauer, Stephan
    Robak, Tadeusz
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Priti
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3441 - +
  • [44] ACALABRUTINIB, A SECOND-GENERATION BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Wierda, W.
    Jones, J.
    Furman, R.
    Stephens, D.
    Devereux, S.
    Brown, J.
    Hillmen, P.
    Hamdy, A.
    Fardis, M.
    Tawashi, M.
    Wang, M. H.
    Patel, P.
    Mittag, D.
    Krantz, F.
    Rothbaum, W.
    Izumi, R.
    O'Brien, S.
    Byrd, J.
    HAEMATOLOGICA, 2016, 101 : 151 - 151
  • [45] Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).
    Byrd, John C.
    Jones, Jeffrey Alan
    Furman, Richard R.
    Stephens, Deborah Marie
    Devereux, Steve
    Brown, Jennifer R.
    Hillmen, Peter
    Hamdy, Ahmed M.
    Fardis, Maria
    Tawashi, Manal
    Wang, Min Hui
    Patel, Priti
    Mittag, Diana
    Krantz, Fanny
    Rothbaum, Wayne
    Izumi, Raquel
    O'Brien, Susan Mary
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Fuerstenau, Moritz
    Robrecht, Sandra
    Giza, Adam
    Fink, Anna
    Fischer, Kirsten
    Langerbeins, Petra
    Al-Sawaf, Othman
    Tausch, Eugen
    Schneider, Christof
    Schetelig, Johannes
    Dreger, Peter
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Schilhabel, Anke
    Brueggemann, Monika
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
  • [47] Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
    Owen, Carolyn J.
    Stewart, Douglas A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (04) : 161 - 170
  • [48] Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer
    Ruppert, Amy S.
    Perez, Gabriela
    Booth, Allison M.
    Feldman, Diane
    Dib, Elie G.
    Jatoi, Aminah
    Le-Rademacher, Jennifer
    Heerema, Nyla A.
    Lozanski, Gerard
    Little, Richard
    Ding, Wei
    Hill, Brian T.
    Stone, Richard M.
    Mandrekar, Sumithra J.
    Byrd, John C.
    BLOOD, 2019, 134
  • [49] An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
    Chen, Christine I.
    Paul, Harminder
    Snitzler, Susi
    Le, Lisa W.
    Wei, Ellen Nong
    Lau, Anthea
    Johnston, James B.
    Gibson, Spencer B.
    Queau, Michelle L.
    Trudel, Suzanne
    BLOOD, 2015, 126 (23)
  • [50] SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
    Stathis, Anastasios
    Mey, Ulrich
    Schar, Sami
    Hitz, Felicitas
    Pott, Christiane
    Mach, Nicolas
    Krasniqi, Fatime
    Novak, Urban
    Schmidt, Christian
    Hohloch, Karin
    Kienle, Dirk Lars
    Hess, Dagmar
    Moccia, Alden A.
    Unterhalt, Michael
    Eckhardt, Katrin
    Hayoz, Stefanie
    Forestieri, Gabriela
    Rossi, Davide
    Dirnhofer, Stefan
    Ceriani, Luca
    Sartori, Giulio
    Bertoni, Francesco
    Buske, Christian
    Zucca, Emanuele
    Hiddemann, Wolfgang
    BLOOD ADVANCES, 2022, 6 (13) : 3911 - 3920
12345